|Dr. Jonathan G. Drachman M.D.||CEO, Pres, Principal Financial Officer & Director||651.29k||N/A||1962|
|Dr. Priti Patel M.D., M.S.||Chief Medical Officer||512.73k||N/A||1976|
|Dr. David Baker||Co-founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Sean Michael Smith||Principal Accounting Officer, VP of Fin. & Controller||N/A||N/A||1986|
|Ms. Donna M. Cochener-Metcalfe J.D.||Gen. Counsel & Sr. VP of Legal||N/A||N/A||1975|
|Dr. Carl Walkey Ph.D.||Sr. VP of Corp. Devel.||N/A||N/A||1985|
|Ms. Samantha Willing||Sr. VP of People & Culture||N/A||N/A||N/A|
|Mr. Kamran Alam||Sr. Strategic Advisor||N/A||N/A||1974|
|Dr. Bill Arthur||VP & Head of Research||N/A||N/A||N/A|
|Mr. Umut Ulge||VP of Clinical Devel.||N/A||N/A||N/A|
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 8; Compensation: 10.